Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Loss of Stem Cell Quiescence and Impaired Stem Cell Function of CD34 + /CD38 low Cells One Year Following Autologous Stem Cell Transplantation

Carolien M Woolthuis, Annet Z Vos, Gerwin Huls, Joost TM de Wolf, Jan J. Schuringa, PhD, Edo Vellenga, PhD

Blood (2011) 118 (21): 1893.

https://doi.org/10.1182/blood.V118.21.1893.1893

Published: 2011

Journal Articles

Influence of Prophylactic Platelet Transfusions on the Recovery of Bone Marrow Function After Intensive Chemotherapy for Acute Myeloid Leukemia.

Roland MH Kivit, Peter Joosten, Mels Hoogendoorn, Joost TM De Wolf

Blood (2010) 116 (21): 1118.

https://doi.org/10.1182/blood.V116.21.1118.1118

Published: 2010

Journal Articles

Influence of Different Dosages of Cyclophosphamide on Stem Cell Mobilization and Engraftment In Newly Diagnosed Multiple Myeloma Patients Treated with a Thalidomide Containing Regimen.

Joost TM De Wolf, Gustaaf Van Imhoff, Gerwin A Huls, Edo Vellenga

Blood (2010) 116 (21): 3494.

https://doi.org/10.1182/blood.V116.21.3494.3494

Published: 2010

Journal Articles

Endothelial Cells In Low-Risk MDS Show Ultrastructural Features of Enhanced Autophagy

Ewout J. Houwerzijl, MD, Nel R. Blom, MLT, Fiona A.J. van den Heuvel, MLT, Johannes J.L. van der Want, PhD, André B Mulder, MD, Joost TM de Wolf, Edo Vellenga, MD

Blood (2010) 116 (21): 2932.

https://doi.org/10.1182/blood.V116.21.2932.2932

Published: 2010

Journal Articles

Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study.

James B. Bussel, MD, David J Kuter, MD, DPhil, Adrian Newland, MD, FRCP, Joost TM de Wolf, MD, Jeffrey Wasser, MD, Paul Chang, Kun Nie, Dietmar Berger, MD, PhD

Blood (2009) 114 (22): 681.

https://doi.org/10.1182/blood.V114.22.681.681

Published: 2009

Journal Articles

Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study

David J Kuter, MD, DPhil, James B Bussel, MD, Adrian Newland, MD, FRCP, Joost TM de Wolf, MD, Troy Guthrie, MD, Jeffrey Wasser, MD, Lara Gehl, Kun Nie, PhD, Dietmar Berger, MD, PhD

Blood (2008) 112 (11): 402.

https://doi.org/10.1182/blood.V112.11.402.402

Published: 2008

NARROW

Loss of Stem Cell Quiescence and Impaired Stem Cell Function of CD34 + /CD38 low Cells One Year Following Autologous Stem Cell Transplantation

Influence of Prophylactic Platelet Transfusions on the Recovery of Bone Marrow Function After Intensive Chemotherapy for Acute Myeloid Leukemia.

Influence of Different Dosages of Cyclophosphamide on Stem Cell Mobilization and Engraftment In Newly Diagnosed Multiple Myeloma Patients Treated with a Thalidomide Containing Regimen.

Endothelial Cells In Low-Risk MDS Show Ultrastructural Features of Enhanced Autophagy

Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study.

Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study

Email alerts

ASH Publications

American Society of Hematology

Loss of Stem Cell Quiescence and Impaired Stem Cell Function of CD34 + /CD38 low Cells One Year Following Autologous Stem Cell Transplantation

Influence of Prophylactic Platelet Transfusions on the Recovery of Bone Marrow Function After Intensive Chemotherapy for Acute Myeloid Leukemia.

Influence of Different Dosages of Cyclophosphamide on Stem Cell Mobilization and Engraftment In Newly Diagnosed Multiple Myeloma Patients Treated with a Thalidomide Containing Regimen.

Endothelial Cells In Low-Risk MDS Show Ultrastructural Features of Enhanced Autophagy

Long-Term Efficacy and Safety of Romiplostim for the Treatment of Patients with Chronic Immune Thrombocytopenia (ITP): 5-Year Update From An Open-Label Extension Study.

Long-Term Treatment with Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura (ITP): 3-Year Update from An Open-Label Extension Study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only